REMstar Plus CPAP Machine

Pittsburgh, PA - April 16, 2001

Respironics, Inc. has announced the launch of REMstar® Plus - the first in a new line of CPAP systems used for the treatment of sleep apnea.

"I am confident that our new REMstar platform will further expand the Company's lead in the expanding sleep disorders breathing market," stated James W. Liken, president and chief executive officer.

The first in a series, the REMstar Plus focuses on two highly important issues -- patient comfort and compliance. The product's most noteworthy change is the unit's integrated approach to humidification; additionally, the REMstar's vast new array of features and its contemporary sleek new look further distinguish this product as a truly unique offering for the sleep market.

"Our first objective was the comfort of the patient," explained Mr. Liken. "It is a fact that when a sleep patient using CPAP experiences discomfort from dry nasal passages, that patient is less likely to comply with their prescribed treatment schedule. Respironics addressed this problem by applying its technical expertise to the issues surrounding humidification; with proper humidification, compliance naturally follows," Mr. Liken continued.

The new platform provides greater flexibility. It gives the healthcare provider the option to transition patients from no humidification, to room temperature humidification, to heated humidification with one device. While doing so, it also gives providers an opportunity to efficiently manage their product inventory.

The introduction of the REMstar platform presents an added benefit to Respironics by allowing the Company to streamline its model offering and simplify market segmentation. The new REMstar Plus will replace four previous models (REMstar LX, REMstar Plus LX, Quest 7300 and Quest 7300H). A sister unit, the REMstar Pro, not yet available, will replace the Aria LX and Quest 7400 models, and will include additional compliance metering options.

Respironics is a recognized resource in the medical device market, having introduced the first commercial CPAP unit in 1985. The company provides innovative products and unique programs to health care providers while helping them to grow and manage their business efficiently. The company's focus is on home care, hospital and international markets providing programs that manage sleep disordered breathing, chronic obstructive pulmonary disease, asthma, infant care and restrictive lung disorders. Further information on Respironics can be found on its website: www.respironics.com.